Teleflex Incorporated – Consensus Indicates 31.0% Upside Potential

Incorporated Teleflex found using the ticker (TFX) now have 9 analysts covering the stock with the consensus suggesting a buy rating. The target price ranges between 430 and 295 calculating the average target price we see 364. Now with the previous close price of 277.78, this indicates that there is 31.0% upside potential. There is a 50-day moving average of 331.8 and the 200-day MA is 345.43. The market cap of the company is $12,645 million. Company website:

The potential market capitalization would be $16,570 million based on market consensus.

You can now share it on Stocktwits, just click on the logo below and add the ticker in the text to be seen.

Teleflex Incorporated designs, develops, manufactures and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that include Arrow-branded catheters, catheter tip navigation and positioning systems, and intraosseous access systems for delivery of intravenous therapies, pressure measurement artery and collection of blood samples via a single puncture site. The Company also offers interventional products, which include various coronary catheters, structural cardiac therapies, and peripheral interventional and cardiac assist products used by interventional cardiologists and radiologists and vascular surgeons; and Arrow brand catheters, Guideline and Trapliner catheters, Manta Vascular Closure devices and Arrow Oncontrol. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine and military channels; and surgical products, including metal and polymer ligation clips and surgical fascial closure systems used in laparoscopic surgical procedures, percutaneous surgical systems and other surgical instruments. The company also offers interventional urology products including the UroLift System, an invasive technology for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry and ventilation management products for use in a variety of care settings. It provides urology products, such as catheters, urine collectors, catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

Comments are closed.